Peregrine Says Phase II Trial Shows Doubling of Survival; Interim Data From Peregrine's Phase II Trial Demonstrate Doubling of Overall Survival Print E-mail
By Staff and Wire Reports   
Friday, 07 September 2012 19:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 7, 2012.

Peregrine Pharmaceuticals (NASDAQ: PPHM)
, announced interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm).

The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.


=====


Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)
, announced interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm).

The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.



Also Friday:



Aetna (NYSE: AET)
today announced the expert panel of judges for its CarePass® Medication Reminder Developer Challenge, which runs through Aug. 17. Launched June 5, the Challenge is focused on developing apps that best help consumers remember to take their medications.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY)
, a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2012, and company highlights.

Array BioPharma Inc. (Nasdaq:ARRY)
will report financial results for the fourth quarter and full year of fiscal 2012 on Monday, August 13, 2012, and will hold a conference call on Tuesday, August 14, 2012 at 9:00 a.m. eastern time to discuss these results.

Axia Group's (PINKSHEETS:AGIJ)
, (www.axiagroup.com) Collagenna Skin Care Products is pleased to announce that it has signed a firm and binding agreement of purchase and sale to acquire an email marketing company.

Bioanalytical Systems, Inc. (NASDAQ:BASI)
will release financial results for the fiscal 2012 third quarter ended June 30, 2012 at approximately 8:30 a.m. EDT on Tuesday, August 14, 2012. BASi has scheduled a conference call at 11:00 a.m. EDT that morning to discuss its results for the quarter.

Boston Therapeutics, Inc. (OTCBB: BTHE)
, headquartered in Manchester, New Hampshire, is a development stage specialty pharmaceutical company that brings proprietary complex carbohydrate chemistry to bear on the commercialization of prescription therapies and over-the-counter dietary supplements that treat Type 2 diabetes.

Celgene Corporation (NASDAQ: CELG)
today announced the successful pricing of two series of senior unsecured notes for an aggregate principal amount of $1.5 billion.

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC)
management will present at the Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 11at 10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific time in the Starlight North room of the Waldorf-Astoria Hotel.

Cempra Inc. (Nasdaq: CEMP)
, a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Sept. 9 to 12.

Cerus Corporation (NASDAQ: CERS)
announced today that Hemakim, Cerus’ distributor for Turkey, has signed an agreement with the Florence Nightingale Hospital, a leading medical center in Turkey, to supply the INTERCEPT Blood System for platelets and plasma.

Champions Oncology, Inc. (OTC: CSBR)
announced that Joel Ackerman, Champions CEO, will present at the Rodman & Renshaw Annual Global Investment Conference, on Monday, September 10, 2012 at 2:50 PM ET.

Charles River Laboratories International, Inc. (NYSE: CRL)
today reported its results for the second quarter of 2012.

Clovis Oncology, Inc. (NASDAQ:CLVS)
today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

Columbia Laboratories, Inc. (Nasdaq: CBRX)
today reported financial results for the three- and six- month periods ended June 30, 2012.

Covidien (NYSE: COV)
, a leading global provider of healthcare products, will host an investor meeting on Thursday, September 13, 2012, to update the investment community on the Company and its growth initiatives, strategic priorities and financial outlook.

CytRx Corporation (NASDAQ: CYTR)
, a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) primarily in patients with advanced soft tissue sarcoma will be featured in a poster presentation at the ESMO (European Society of Medical Oncology) 2012 Congress being held September 28 - October 2 in Vienna, Austria.

Derma Sciences, Inc. (Nasdaq: DSCI)
, a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on August 14, 2012 to discuss the financial results for the second quarter of 2012.

Dr. Reddy’s Laboratories (NYSE: RDY)
announced today that it has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequivalent generic versions of SINGULAIR® Tablets and Chewable tablets, in the US market on August 6, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA.

Elan Corporation, plc (NYSE:ELN)
announced today that Johnson & Johnson has issued a press release regarding the discontinuation of Phase 3 development of bapineuzumab IV in mild to moderate Alzheimer’s.

Emergent BioSolutions Inc. (NYSE: EBS)
announced today that the company will be webcasting its presentation at the Wedbush 2012 Life Sciences Management Access Conference in New York on Tuesday, August 14, 2012 at 8:00 AM Eastern.

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today reported net income of $3.0 million for the three months ended June 30, 2012 and a reduced net loss for the six months ended June 30, 2012 to $0.6 million, primarily as a result of the Company’s sale of its Ceplene®-related assets and contract rights to Meda AB.

Exact Sciences Corp. (Nasdaq: EXAS)
today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Exactech, Inc. (Nasdaq: EXAC)
, a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials will update investors at the 2012 Canaccord Genuity Growth Conference in Boston on Tuesday, August 14, 2012.

Fluidigm Corporation (NASDAQ:FLDM)
today announced its financial results for the second quarter ended June 30, 2012.

GenMark Diagnostics, Inc. (Nasdaq:GNMK)
, a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the second quarter ended June 30, 2012.

Globus Medical, Inc. (NYSE:GMED)
, a leading spinal implant manufacturer, today announced the pricing of its initial public offering of 8,333,333 shares of Class A common stock at a price of $12 per share, consisting of 2,083,333 shares offered by Globus Medical and 6,250,000 shares offered by selling stockholders.

GTx, Inc. (Nasdaq: GTXI)
today provided a Company update and reported financial results for the second quarter of 2012.

ImmunoGen, Inc. (Nasdaq: IMGN)
, a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2012 and provided an update on the Company.

Incyte Corporation (Nasdaq:INCY)
announced today it will present at the 32nd Annual Canaccord Genuity Growth Conference on Wednesday, August 15 at 10:30 a.m. (ET) in Boston.

Interleukin Genetics, Inc. (OTCQB: ILIU)
announced today that it will host a conference call and Webcast on Tuesday, August 14, 2012 at 4:30 p.m. ET to discuss the Company’s second quarter results.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
today highlighted its recent clinical and business progress and reported its financial results for the second quarter of 2012.

Insulet Corporation (NASDAQ: PODD)
, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the Company will participate in the 10th Annual CL King Best Ideas Conference at the Omni Berkshire Place Hotel in New York City.

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH)
announced today the publication in the July 2012 Journal of Clinical Microbiology of a clinical study that supports validation of a new clinical diagnostic test for bacterial vaginosis.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)
announced today that Arthur Sands, M.D., Ph.D., President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, at 8:00 a.m. EST in New York City.

MannKind Corporation (Nasdaq: MNKD)
today reported financial results for the second quarter ended June 30, 2012.

Maxygen, Inc. (Nasdaq: MAXY)
, a biotechnology company, today announced financial and business results for the quarter ended June 30, 2012.

Medical Marijuana, Inc. (OTC: MJNA)
, a leading hemp industry innovator, is pleased to announce that its portfolio company PhytoSPHERE Systems, which develops pharmaceutical grade medicinal hemp production facilities that produce high grade oil, is harvesting 1,000 acres of Hemp from its microclimate fields throughout Europe.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB)
, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced business highlights and consolidated results for the second quarter and six months ended June 30, 2012.

OPKO Health, Inc. (NYSE:OPK)
today announced its acquisition of Farmadiet Group Holding, S.L., a Barcelona-based company currently engaged in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products.

Pall’s (NYSE:PLL)
2011-2012 Laboratory Filtration, Separation and Detection Products Catalog is now available in an easy-to-use, interactive digital format. Pall’s catalog provides a convenient, all-in-one guide to the company’s line of laboratory-scale products.

Palatin Technologies, Inc. (NYSE MKT: PTN)
today announced that its collaboration partner,  AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity.  

PerkinElmer, Inc. (NYSE: PKI)
, a global leader focused on improving the health and safety of people and the environment, today announced the publication of its 2011 Corporate Social Responsibility (CSR) Report.

Pfizer Inc. (NYSE: PFE)
announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

Premier Biomedical, Inc. (OTCBB: BIEI)
announced that they have begun trading on the OTC-BB fully reporting index at “BIEI”. Premier Biomedical Inc’s principal technology is based on the Felder Doctrine™, “To physically remove the pathophysiologic basis of the disease.”

Puma Biotechnology, Inc. (OTCBB:PBYI)
, a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 12:45 p.m. EDT on Tuesday, August 14, at the Wedbush PacGrow 2012 Life Sciences Management Access Conference in New York.

Pfizer Inc. (NYSE: PFE)
announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) in patients with overactive bladder (OAB) met its primary endpoint.

Sangamo BioSciences, Inc. (Nasdaq: SGMO)
announced today that Edward Lanphier, Sangamo’s president and CEO, will provide an update on the progress of Sangamo’s ZFP Therapeutic®development programs and an overview of the company’s business strategy at 9:10 am ET on Tuesday, August 14, 2012, at the 2012 Wedbush PacGrow Lifesciences Management Access Conference which will be held in New York City.

Santarus, Inc. (NASDAQ: SNTS)
, a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2012.

Senomyx, Inc. (NASDAQ:SNMX)
, a company using proprietary taste science technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries, today provided a corporate update and reported financial results for the second quarter ended June 30, 2012.

Spectrum Pharmaceuticals (NasdaqGS: SPPI)
, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Rodman & Renshaw Annual Global Investment Conference being held at The Waldorf-Astoria in New York City. The Company presentation is on Monday, September 10, 2012, at 11:15 AM ET.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)
, a global pharmaceutical company, today reported its consolidated financial results for the quarter and six months periods ended June 30, 2012.

Targacept, Inc. (NASDAQ: TRGT)
, a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the second quarter and six months ended June 30, 2012.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three month period ended June 30, 2012.

Tornier N.V. (NASDAQ:TRNX)
, a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, today reported its financial results for the second quarter of 2012 and updated its fiscal 2012 financial outlook.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter